In addition, tislelizumab (BGB-A317), a humanized IgG4 anti-PD-1 monoclonal antibody, has shown anti-tumor potential in advanced solid tumors more evidently at the 5 mg/kg dose [144]. Here, PDCD1 is linked to neoplasm.